April 13, 2018 / 8:50 PM / 3 months ago

BRIEF-Bristol-Myers Says Opdivo To Demonstrate Superior Survival Benefit Compared With Chemotherapy In A Predominantly Chinese Population With Previously Treated Non Small Cell Lung Cancer

April 13 (Reuters) - Bristol-Myers Squibb Co:

* OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON -SMALL CELL LUNG CANCER (NSCLC)

* IN PHASE 3 CHECKMATE-078 TRIAL, OPDIVO REDUCED RISK OF DEATH BY 32% VERSUS CHEMOTHERAPY

* IN STUDY, OPDIVO DEMONSTRATED A STATISTICALLY SIGNIFICANT BENEFIT VERSUS DOCETAXEL ON PRIMARY ENDPOINT OF OVERALL SURVIVAL

* IN TRIAL, TWO SECONDARY ENDPOINTS OF ORR, MEDIAN DURATION OF RESPONSE DEMONSTRATED DURABILITY WITH OPDIVO VERSUS DOCETAXEL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below